

LITERATURA

1. Decraene V, Ghebrehewet S, Dardamissis E, et al. An outbreak of multidrug-resistant *Pseudomonas aeruginosa* in a burns service in the North of England: challenges of infection prevention and control in a complex setting. *J Hosp Infect.* 2018 Dec; 100(4): e239–e245. doi: 10.1016/j.jhin.2018.07.012.
2. Slaviero L, Avruscio G, Vindigni V, Tocco-Tussardi I. Antiseptics for burns: a review of the evidence. *Ann Burns Fire Disasters.* 2018 Sep 30; 31(3): 198–203.
3. Wang Y, Beekman J, Hew J, Jackson S, Issler-Fisher AC, Parungao R, Lajevardi SS, Li Z, Maitz PKM. Burn injury: Challenges and advances in burn wound healing, infection, pain and scarring. *Adv Drug Deliv Rev.* 2018 Jan 1; 123: 3–17. doi: 10.1016/j.addr.2017.09.018.
4. Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/Tazobactam: A Novel Cephalosporin/ β -Lactamase Inhibitor Combination. *Pharmacotherapy.* 2015 Jul; 35(7): 701–715. doi: 10.1002/phar.1609.
5. Larson KB, Patel YT, Willavize S, Bradley JS, Rhee EG, Caro L, Rizk ML. Ceftolozane/tazobactam population pharmacokinetics and dose selection for further clinical evaluation in pediatric patients with complicated urinary tract or complicated intraabdominal infections. *Antimicrob Agents Chemother.* 2019 Apr 8. pii: AAC.02578-18. doi: 10.1128/AAC.02578-18.
6. Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013–2015). *Int J Antimicrob Agents.* 2018 Feb; 51(2): 181–189. doi: 10.1016/j.ijantimicag.2017.09.016.
7. Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane-Tazobactam Activity against *Pseudomonas aeruginosa* Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. *Antimicrob Agents Chemother.* 2017 Jun 27; 61(7). pii: e00465–17. doi: 10.1128/AAC.00465-17.
8. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis.* 2016 Sep 1; 63(5): e61–e111. doi: 10.1093/cid/ciw353.
9. Sousa Dominguez A, Perez-Rodríguez MT, Nodar A, Martínez-Lamas L, Perez-Landeiro A, Crespo Casal M. Successful treatment of MDR *Pseudomonas aeruginosa* skin and soft-tissue infection with ceftolozane/tazobactam. *J Antimicrob Chemother.* 2017 Apr 1; 72(4): 1262–1263. doi: 10.1093/jac/dkw526.
10. Castaldo N, Givone F, Peghin M, Righi E, Sartor A, Bassetti M. Multidrug-resistant *Pseudomonas aeruginosa* skin and soft-tissue infection successfully treated with ceftolozane/tazobactam. *J Glob Antimicrob Resist.* 2017 Jun; 9: 100–102. doi: 10.1016/j.jgar.2017.02.012.
11. Dietl B, Sánchez I, Arcenillas P, et al. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant *Pseudomonas aeruginosa*: clinical and microbiological outcomes. *Int J Antimicrob Agents.* 2018 Mar; 51(3): 498–502. doi: 10.1016/j.ijantimicag.2017.11.003.
12. Gentile I, Buonomo AR, Maraolo AE, Scotto R, De Zottis F, Di Renzo G, Borgia G. Successful treatment of post-surgical osteomyelitis caused by XDR *Pseudomonas aeruginosa* with ceftolozane/tazobactam monotherapy. *J Antimicrob Chemother.* 2017 Sep 1; 72(9): 2678–2679. doi: 10.1093/jac/dkx172.
13. Skoglund E, Ledesma KR, Lasco TM, Tam VH. Ceftolozane/tazobactam activity against meropenem-non-susceptible *Pseudomonas aeruginosa* bloodstream infection isolates. *J Glob Antimicrob Resist.* 2017 Dec; 11: 154–155. doi: 10.1016/j.jgar.2017.10.016.
14. Aitken SL, Kontoyiannis DP, DePombo AM, Bhatti MM, Tverdek FP, Gettys SC, Nicolau DP, Nunez CA. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant *Pseudomonas aeruginosa* Bloodstream Infection in a Pediatric Leukemia Patient. *Pediatr Infect Dis J.* 2016 Sep; 35(9): 1040–1042. doi: 10.1097/INF.0000000000001228.